InnoCare Pharma Ltd - ESG Rating & Company Profile powered by AI
If you are employed by InnoCare Pharma Ltd and you wish to licence your ESG aseessment, please contact us. This ESG score for InnoCare Pharma Ltd represents its transparency towards the UN Sustainable Development Goals. This analysis of InnoCare Pharma Ltd uses intelligence from across the web as well as from available disclosures by InnoCare Pharma Ltd.
InnoCare Pharma Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 2.7, social score of 3.4 and governance score of 2.7.
2.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1336 | SyneuRx International (Taiwan) Corp | 3.0 | Medium |
| 1336 | Sensorion SA | 3.0 | Medium |
| 1353 | InnoCare Pharma Ltd | 2.9 | Medium |
| 1353 | Caribou Biosciences Inc | 2.9 | Medium |
| 1353 | Checkmate Pharmaceuticals Inc | 2.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does InnoCare Pharma Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes InnoCare Pharma Ltd report the average age of the workforce?
Sign up for free to unlockDoes InnoCare Pharma Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes InnoCare Pharma Ltd offer flexible work?
Sign up for free to unlockDoes InnoCare Pharma Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes InnoCare Pharma Ltd conduct supply chain audits?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes InnoCare Pharma Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose water use targets?
Sign up for free to unlockDoes InnoCare Pharma Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid InnoCare Pharma Ltd have a product recall in the last two years?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes InnoCare Pharma Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas InnoCare Pharma Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose parental leave metrics?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes InnoCare Pharma Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes InnoCare Pharma Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs InnoCare Pharma Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose its waste policy?
Sign up for free to unlockDoes InnoCare Pharma Ltd report according to TCFD requirements?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose energy use targets?
Sign up for free to unlockDoes InnoCare Pharma Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes InnoCare Pharma Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for InnoCare Pharma Ltd
These potential risks are based on the size, segment and geographies of the company.
InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It offers Orelabrutinib (ICP-022), a Bruton's tyrosine kinase for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed and refractory mantle cell lymphoma. ICP-022 is in Phase II studies for patients with relapsed and refractory marginal zone lymphoma, relapsed and refractory central nervous system lymphoma, and relapsed and refractory Waldenstrom's macroglobulinemia; and in a Phase I clinical trial for follicular lymphoma patients, as well as Phase I basket trial for B-cell malignancies. The company is developing Gunagratinib( ICP-192), a pan-inhibitor of fibroblast growth factor receptor (FGFR) that is in Phase I/IIa clinical trial to define its maximum tolerated dose and/or optimal biological dose, and pharmacokinetics/ pharmacodynamics in patients with solid tumors; and ICP-105, a FGFR4 inhibitor, which is in Phase I dose escalation trial for the treatment of advanced hepatocellular carcinoma. It is also developing ICP-723, a pan-inhibitor of tropomyosin-related kinase family that is in Phase I clinical trial to treat patients with neurotrophic tyrosine receptor kinase fusion-positive cancers; and ICP-332, a small-molecule inhibitor of tyrosine kinase 2 for the treatment of various T-cell mediated autoimmune disorders, such as psoriasis, inflammatory bowel disease, and systemic lupus erythematosus. The company was incorporated in 2015 and is headquartered in Beijing, China.